Preclinical studies involve biochemical and biophysical characterization of the antibodies and peptides, as well as functional evaluation of their activity in in vitro and in vivo assays. These assays are performed on laboratory animal cells, and their purpose is to document information on efficacy, safety, and pharmacological characteristics that precede the conduction of clinical tests in human beings.

For the characterization of ReceptaBio antibodies and peptides, preclinical studies were performed in part by ReceptaBio researchers, but also counting with several partnerships in Brazil and abroad.

Analytical studies and affinity assays were performed by the ReceptaBio team at the Monoclonal Antibodies Laboratory at the Butantan Institute, in collaboration with Prof. Dr. Ana Maria Moro, for the RebmAb100 and RebmAb200 antibodies.

Functional characterization, with in vivo assays, were conducted for RebmAb200 antibody by ReceptaBio researchers, in the laboratories of the Center of Nuclear Medicine of the Hospital das Clínicas of FMUSP (CMN-HCFMUSP), in collaboration with Prof. Dr. Carlos Alberto Buchpiguel, Director of CMN-HCFMUSP and Prof. Dr. Roger Chammas, Full Professor of Department of Experimental Oncology, FMUSP. For peptides, the assays are carried out in the Department of Microbiology, Immunobiology and Parasitology, Unit of Experimental Oncology, under the coordination of Prof. Dr. Luiz Travassos.

On the other hand, immune-histochemistry tests aim to determine the biochemical affinity of the antibodies with normal and tumor tissues of different types of neoplasia. Immuno-histochemistry of ReceptaBio’s RebmAb100, 200, 300 and 400 antibodies was carried out by researchers from the Laboratory of Medical Investigation 14 (LIM-14), College of Medicine, University of São Paulo, under the coordination of Prof. Dr. Venâncio Avancini Alves, Full Professor of Pathology, internationally renowned scientist in the area.